Probing brain reward system function in major depressive disorder: Altered response to dextroamphetamine

Archives of General Psychiatry

Volumn 59, Issue 5, 2002, Pages 409-416

  Tremblay, Lescia K ^a   Naranjo, Claudio A ^a,b   Cardenas, Laura ^a,b   Herrmann, Nathan ^a,b   Busto, Usoa E ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMPHETAMINE; PLACEBO;

ADULT; ANHEDONIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOPAMINE RELEASE; DOUBLE BLIND PROCEDURE; FEMALE; HAMILTON SCALE; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; REWARD; SELF REPORT;

EID: 0036244630     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.59.5.409     Document Type: Article

References (84)

1. The neurobiology of depression
2. Evidence for a biochemical lesion in depression
3. Cingulate function in depression: A potential predictor of treatment response
4. Subgenual prefrontal cortex abnormalities in mood disorders
5. Blunted left cingulate activation in mood disorder subjects during a response interference task (the Stroop)
6. Reciprocal limbic-cortical function and negative mood: Converging PET findings in depression and normal sadness
7. Hypofrontality and negative symptoms in major depressive disorder
8. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression
9. Glial reduction in the subgenual prefrontal cortex in mood disorders
10. The catecholamine hypothesis of affective disorders: A review of supporting evidence
11. Intensification of the central serotonergic processes as a possible determinant of the thymoleptic effect
12. Monoamine dysfunction and the pathophysiology and treatment of depression
13. Are all antidepressants the same?
14. Linking mind and brain in the study of mental illnesses: A project for a scientific psychopathology
15. The organization of networks within the orbital and medial prefrontal cortex of rats, monkeys and humans
16. Drug addiction, dysregulation of reward and allostasis
17. Drug-activation of brain reward pathways
18. Positive reinforcement produced by electrical stimulation of the septal area and other regions of the rat brain
19. Addictive drugs and brain stimulation reward
20. Drugs of abuse and the brain
21. Dopamine neurons and their role in reward mechanisms
22. Nicotine-induced limbic cortical activation in the human brain: A functional MRI study
23. Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D2 receptors
24. SPECT imaging of striatal dopamine release after amphetamine challenge
25. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria
26. Drug abuse: Hedonic homeostatic dysregulation
27. The role of the brain reward system in depression
28. Dual effects of d-amphetamine on dopamine neurons mediated by dopamine and nondopamine receptors
29. Effect of amphetamine on extracellular acetylcholine and monoamine levels in subterritories of the rat medial prefrontal cortex
30. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine
31. Mechanism of the dopamine-releasing actions of amphetamine and cocaine: Plasmalemmal dopamine transporter versus vesicular monoamine transporter
32. Amphetamine: Effects on catecholamine systems and behaviour
33. Hedonic valence, dopamine and motivation
34. Drug preference and mood in humans: Preference for d-amphetamine and subject characteristics
35. The neuroendocrine and behavioral response to dextroamphetamine in normal individuals
36. Endogenomorphic depression: A conceptual and terminological revision
37. Anhedonia: A general nosology surmounting correlate of a dysfunctional dopaminergic reward system?
38. Neurobiological dimensions of depression and mania
39. Reciprocal changes in prefrontal and limbic dopamine responsiveness to aversive and rewarding stimuli after chronic mild stress: Implications for the psychobiology of depression
40. Validity, reliability and utility of the chronic mild stress model of depression: A 10-year review and evaluation
41. A rating scale for depression
42. The Addiction Research Center Inventory: Standardization of scales which evaluate subjective effects of morphine, amphetamine, pentobarbital, alcohol, LSD-25, pirahexl and chloropromazine
43. Assessment of the abuse liability of buspirone in recreational sedative users
44. Highly sensitive method for the quantitation of homovanillic acid in cerebrospinal fluid
45. Assay for simultaneous determination of fenfluramine and norfenfluramine in human plasma and urine
46. Issues and recommendations regarding use of the Beck Depression Inventory
47. A scale for the assessment of hedonic tone: The Snaith-Hamilton Pleasure Scale
48. Drug preferenceand mood in humans: d-amphetamine
49. Reliability, validity and clinical application of the Visual Analogue Mood Scale
50. Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans
51. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder
52. Inhibition of P4502D6 modifies codeine abuse liability
53. Does extent of p-hydroxylation alter methamphetamine kinetics?
54. Diltiazem, a calcium chanel antagonist, partly attenuates the effects of dextroamphetamine in healthy volunteers
55. Separate mechanisms for behavioral, cardiovascular, and hormonal responses to dextroamphetamine in man
56. Acute tolerance to subjective but not cardiovascular effects of d-amphetamine in normal, healthy men
57. Carvedilol affects the physiological and behavioral response to smoked cocaine in humans
58. A quantitative magnetic resonance imaging study of caudate and lenticular nucleus gray matter volume in primary unipolar major depression: Relationship to treatment response and clinical severity
59. 123I]β-CIT
60. Individual differences in the subjective response to smoked cocaine in humans
61. The reinforcing properties of amphetamine in overweight subjects and subjects with depression
62. Amphetamine, but not methylphenidate, predicts antidepressant efficacy
63. Heterogeneity of mesotelencephalic dopamine fibers: Physiology and pharmacology
64. Association between age-related decline in brain dopamine activity and impairment in frontal and cingulate metabolism
65. Nigrostriatal system plasticity in Parkinson's disease: Effect of dopaminergic denervation and treatment
66. Effects of alphamethyl-paratyrosine (AMPT) in drug-free depressed patients
67. 2 receptors in depression measured with single photon emission computed tomography
68. Clinical and psychometric correlates of dopamine D2 binding in depression
69. 123I] IBZM SPECT
70. 2 receptor SPECT before and after antidepressant therapy
71. Psychomotor retardation and anhedonia in depression
72. Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation
73. Neuropharmacological mechanisms of drug reward: Beyond dopamine in the nucleus accumbens
74. Role of 5-HT(2C) receptors in the control of dopamine function
75. Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex
76. Stimulus effects of d-amphetamine II: DA, NE, and 5-HT mechanisms
77. Subtyping depression: Testing algorithms and identification of a tiered model
78. The neurobiology of sexual function
79. The role of stress in the pathophysiology of the dopaminergic system
80. Age-related cognitive deficits mediated by changes in the striatal dopamine system